Recent developments in herpesvirus therapy

Herpes

Volumn 8, Issue 1, 2001, Pages 12-16

  Naesens, L ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiherpes drugs; Cytomegalovirus (CMV); Herpes simplex virus (HSV); Herpesvirus therapy; Nucleoside analogues; Varicella zoster virus (VZV)

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 [1,2 BIS(HYDROXYMETHYL)CYCLOPROPYLMETHYL]GUANINE; ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; PENCICLOVIR; SORIVUDINE; TOMEGLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG MECHANISM; HERPES; HERPES VIRUS; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VARICELLA ZOSTER VIRUS;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BROMODEOXYURIDINE; CLINICAL TRIALS; CYTOSINE; FOSCARNET; GANCICLOVIR; GUANINE; HERPESVIRIDAE INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; THIONUCLEOTIDES; VALINE;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 0035066472     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 9-(2-hydroxy-ethoxymethyl)guanine activity against viruses of the herpes group
2. Current antiviral agents fact file: 2000-2001 update. Part I - Herpesviruses, hepatitis viruses and respiratory, viruses
3. Human herpesviruses: A consideration of the latent state
4. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
5. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel
6. Mechanism of action and selectivity of acyclovir
7. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase
8. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir
9. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
10. The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses
11. Synthesis and antiviral properties of 5-vinyl-pyrimidine nucleoside analogs
12. Mechanism of action of foscarnet against viral polymerases
13. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
14. Resistant herpes simplex virus type 1 infection: An emerging concern after allogeneic stem cell transplantation
15. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
16. Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants
17. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
18. Recent advances in varicella-zoster virus infection
19. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults
20. Valacyclovir for the prevention of cytomegalovirus virus disease after renal transplantation
21. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival
22. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
23. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: Case-control and historical cohort studies
24. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus
25. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients
26. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group
27. Recent advances in the therapy and prevention of CMV infections
28. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
29. Human β-herpesvirus interactions in solid organ transplant recipients
30. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
31. Valganciclovir (VGCV) vs IV ganciclovir as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis: A randomized, controlled study
32. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study
33. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient
34. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
35. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study
36. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: A phase I/II study
37. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
38. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report
39. Synthesis and antiviral activity of novel acyclic nucleosides: Discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses
40. Mode of action of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl) cycloprop-1′-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus
41. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial
42. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis
43. Sorivudine: A promising drug for the treatment of varicella-zoster virus infection
44. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
45. Fomivirsen - A phosphorothioate oligonucleotide for the treatment of CMV retinitis
46. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
47. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease
48. HCMV UL97 is important for late events in viral replication
49. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency
50. In vivo anti-CMV activity, safety and pharmacokinetics of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding
51. Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes
52. Safety, tolerability and pharmacokinetics of BAY 38-4766 - A novel non-nucleoside inhibitor of HCMV replication - In healthy male subjects
53. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
54. The herpesvirus proteases as targets for antiviral chemotherapy